Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Brain Tumor Pathology
Published in: Brain Tumor Pathology 2/2019

01-04-2019 | Ependymoma | Original Article

Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome

Authors: Atsushi Sasaki, Junko Hirato, Takanori Hirose, Kohei Fukuoka, Yonehiro Kanemura, Naohito Hashimoto, Yoshinori Kodama, Koichi Ichimura, Hiroaki Sakamoto, Ryo Nishikawa

Published in: Brain Tumor Pathology | Issue 2/2019

Login to get access

Abstract

We focused on histological and immunohistochemical characteristics of ependymoma (EPN) with molecular profiles to develop more reproducible criteria of the diagnosis. Three expert neuropathologists reviewed the pathology of 130 samples from the Japan Pediatric Molecular Neuro-Oncology Group study. Confirmed cases were assessed for histology, surrogate markers, molecular subgrouping, and survival data. We reached a consensus regarding the diagnosis of EPNs in 100% of spinal cord tumors and 93% of posterior fossa (PF) tumors that had been diagnosed as EPNs by local pathologists, whereas we reached a consensus regarding only 77% of the local diagnosis of supratentorial (ST) EPNs. Among the PF-EPNs, most of anaplastic ependymomas (AEPNs) were defined as EPN-A by methylation profiling, which was significantly correlated with the subgroup assignment. Regarding prognosis, the overall survival of patients with PF-EPN was significantly better than that of patients with PF AEPN (p = 0.01). Histologically, all ependymoma, RELA fusion-positive (EPN-RELA) qualified as Grade III. Both L1 cell adhesion molecule and nuclear factor kappaB p65 antibodies showed good sensitivity for detecting EPN-RELA. This study indicated that the expert consensus pathological diagnosis could correlate well with the molecular classifications in EPNs. ST EPNs should be diagnosed more carefully by histological and molecular analyses.
Literature
1.
Ellison DW, McLendon R, Wiestler OD et al (2016) Ependymoma. In: Louis DN, Ohgaki H. Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system. Fourth Edition revised. IARC press, Lyon, pp 106–111
2.
Healey EA, Barnes PD, Kupsky WJ et al Scott RM, Sallan SE, Black PM, Tarbell NJ (1991) The prognostic significance of postoperative residual tumor in ependymoma. Neurosurgery 28:666–671CrossRef
3.
Ikezaki K, Matsushima T, Inoue T et al (1993) Correlation of microanatomical localization with postoperative survival in posterior fossa ependymomas. Neurosurgery 32:38–44CrossRefPubMed
4.
Pollack IF, Gerszten PC, Martinez AJ et al (1995) Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery 37:655–666CrossRefPubMed
5.
van Veelen-Vincent ML, Pierre-Kahn A, Kalifa C et al (2002) Ependymoma in childhood: prognostic factors, extent of surgery, and adjuvant therapy. J Neurosurg 97:827–835CrossRefPubMed
6.
Metellus P, Barrie M, Figarella-Branger D et al (2007) Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. Brain 130:1338–1349CrossRef
7.
Ellison DW, Kocak M, Figarella-Branger D et al (2011) Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negative Results Biomed 10:7CrossRef
8.
Pajtler K, Mack SC, Ramaswamy V et al (2017) The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variant. Acta Neuropathol 133:5–12CrossRefPubMed
9.
Acquaye A, Vera E, Gilbert MR et al (2017) Clinical presentation and outcomes for adult ependymoma patients. Cancer 123:494–501CrossRefPubMed
10.
11.
Pajtler KW, Witt H, Sill M et al (2015) Molecular classification of ependymal tumors across all CNS compartments. Histopathological grades, and age groups. Cancer Cell 27:728–743CrossRefPubMedPubMedCentral
12.
Figarella-Branger D, Lachapt-Zalcman E, Tobouret E et al (2016) Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. Neuro-Oncol 18:919–927CrossRefPubMedPubMedCentral
13.
Nakamura T, Fukuoka K, Ikeda J et al (2017) Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma. Brain Tumor Pathol 34:160–164CrossRefPubMed
14.
Onishi S, Yamasaki F, Nakano Y et al (2018) RELA fusion-positive anaplastic ependymoma: molecular characterization and advanced MR imaging. Brain Tumor Pathol 35:41–45CrossRefPubMed
15.
Witt H, Mack SC, Ryzhova M et al (2011) Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20:143–157CrossRefPubMedPubMedCentral
16.
Sasaki A, Yokoo H, Tanaka Y et al (2013) Characterization of microglia/macrophages in gliomas developed in S-100βv-erbB transgenic rats. Neuropathology 33:505–514PubMed
17.
18.
Wani K, Armstrong TS, Vera-Bolanos E et al (2012) Collaborative Ependymoma Research Network. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol 123:727–738CrossRefPubMedPubMedCentral
19.
Hoffman LM, Donson AM, Nakachi I et al (2014) Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma. Acta Neuropathol 127:731–745CrossRefPubMed
20.
Tihan T, Zhou T, Holmes E et al (2008) The prognostic value of histological grading of posterior fossa ependymomas in children: a Children’s Oncology Group study and a review of prognostic factors. Mod Pathol 21:165–177CrossRefPubMed
21.
Rezai AR, Woo HH, Lee M et al (1996) Disseminated ependymomas of the central nervous system. J Neurosurg 85:618–624CrossRefPubMed
22.
Prayson RA (1998) Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases. Am J Clin Pathol 110:629–634CrossRefPubMed
23.
Figarella-Branger D, Civatte M, Bouvier-Labit C et al (2000) Prognostic factors in intracranial ependymomas in children. J Neurosurg 93:605–613CrossRefPubMed
24.
Wolfsberger S, Fischer I, Hoftberger R et al (2004) Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am J Surg Pathol 28:914–920CrossRefPubMed
25.
Kurt E, Zheng PP, Hop WC et al (2006) Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer 106:388–395CrossRefPubMed
26.
Araki A, Chocholous M, Gojo J et al (2016) Chromosome 1q gain ad tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma. Acta Neuropathol Commun 4:88–97CrossRefPubMedPubMedCentral
27.
Bayliss J, Mukherjee P, Lu C et al (2016) Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Sci Transl Med 8:366ra161CrossRefPubMedPubMedCentral
28.
Panwalkar P, Clark J, Ramaswamy V et al (2017) Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 134:705–714CrossRefPubMedPubMedCentral
29.
30.
Suzuki T, Izumoto S, Fujimoto Y et al (2005) Clinicopathological study of cellular proliferation and invasion in gliomatosis cerebri: important role of neural cell adhesion molecule L1 in tumour invasion. J Clin Pathol 58:166–171CrossRefPubMedPubMedCentral
31.
Pietsch T, Wohlers I, Goschzik T et al (2014) Supratentorial epoendymomas of childfood carry C11orf95-RELA fusions leading to pathological activation of the NF-κB signalling pathway. Acta Neuropathol 127:609–611CrossRefPubMed
32.
Wang H, Wang H, Zhang W et al (2004) Analysis of the activation status of Akt, NFκB, and Stat3 in human diffuse gliomas. Lab Invest 84:941–951CrossRefPubMed
33.
Min KW, Scheithauer BW (1997) Clear cell ependymoma: a mimic of oligodendroglioma: clinicopathologic and ultrastructural considerations. Am J Surg Pathol 21:820–826CrossRefPubMed
34.
Fouladi M, Helton K, Dalton J et al (2003) Clear cell ependymoma: a clinicopathologic and radiographic analysis of 10 patients. Cancer 98:2232–2244CrossRefPubMed
35.
Tihan T, Burger PC (2016) Ependymoma. In: Kleinschmidt-deMasters BK, Rodriguez FJ, Tihan T (eds) Diagnostic pathology neuropathology, 2 edn. Elsevier, Inc, Salt Lake City
36.
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820CrossRef
37.
Liu Z, Li J, Liu Z et al (2014) Supratentorial cortical ependymoma: case series and review of the literature. Neuropathology 34:243–252CrossRefPubMed
Metadata
Title
Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome
Authors
Atsushi Sasaki
Junko Hirato
Takanori Hirose
Kohei Fukuoka
Yonehiro Kanemura
Naohito Hashimoto
Yoshinori Kodama
Koichi Ichimura
Hiroaki Sakamoto
Ryo Nishikawa
Publication date
01-04-2019
Publisher
Springer Singapore
Published in
Brain Tumor Pathology / Issue 2/2019
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-019-00338-x

Other articles of this Issue 2/2019

Brain Tumor Pathology 2/2019 Go to the issue

Review Article

Pathologic and molecular aspects of anaplasia in circumscribed gliomas and glioneuronal tumors

Review Article

Pilomyxoid astrocytomas: a short review

Acknowledgment

Reviewers in 2018

Instructional Lecture

Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors

Preface

Preface

Review Article

Molecular genetics and therapeutic targets of pediatric low-grade gliomas